myESMO Profile Banner
ESMO - Eur. Oncology Profile
ESMO - Eur. Oncology

@myESMO

Followers
81K
Following
31K
Media
6K
Statuses
20K

The European Society for Medical Oncology (ESMO) is a reference organisation for cancer education and information, supporting the oncology community’s work.

Lugano - Switzerland
Joined August 2009
Don't wanna be here? Send us removal request.
@myESMO
ESMO - Eur. Oncology
1 hour
#ESMOImmuno25 Awardee, @DrIgMelero, discusses how current #immunotherapy can be improved upon with the use of synergistic approaches including combination therapies and targeting resistance mechanisms. Full interview in the #ESMODailyReporter ➡️ https://t.co/n48zARH4qh
0
0
1
@myESMO
ESMO - Eur. Oncology
5 hours
📣 #ESMOImmuno25: A. Marabelle, I.M. Svane and S. Quezada welcome you to the ESMO Immuno-Oncology Congress 2025, an international event to explore the science driving the next generation of cancer care. #esmomeetings 🔗 https://t.co/P27qku2bdW
0
1
5
@myESMO
ESMO - Eur. Oncology
11 hours
🌍 Uniting the Asia-Pacific oncology community! ESMO Asia 2025: 4,550+ participants, 170+ speakers, 71 sessions & 940+ abstracts shared. 🙌 A record-breaking milestone for oncology in Asia! #ESMOAsia25 #esmomeetings 🔗 https://t.co/ipOjagiH5t
0
5
14
@Annals_Oncology
Annals of Oncology
1 day
🆕article in press: Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer (DUO-O) https://t.co/A0CUDkQUC5
0
15
48
@myESMO
ESMO - Eur. Oncology
1 day
ESMO supported the development of the @IARCWHO Teaching Toolkit on identifying carcinogenic hazards to humans. The third module of the series is now available via the IARC Learning space on the WHO Academy.
@IARCWHO
IARC
2 days
Are you involved in teaching evidence-based cancer prevention to different categories of professionals? This new teaching toolkit on Identification of Carcinogenic Hazards to Humans! https://t.co/UsgyZ8vszT @myESMO
0
0
5
@DrAngelaLamarca
Angela Lamarca
3 days
Safe travels everyone 🛫 See you all in @myESMO #ESMOAsia26 😊
1
3
16
@DrHongchengZhu
Hongcheng Zhu 祝鸿程
3 days
Join this global community of @myESMO which is across oncology worldwide, including huge opportunities for #YoungOncologists #ESMOAsia25 #ESMOYOC #ESMOMembership
@ravikanesvaran
Ravindran Kanesvaran
5 days
Consider joining @esmo as a member at #ESMOAsia25 with this amazing deal and be part of a 50k strong membership family! @myESMO
1
2
11
@DrAngelaLamarca
Angela Lamarca
3 days
(my) Conclusions in a challenging topic #IntermediateStage #HCC The key is probably to select the best approach for each patient (MDT) When TACE alone? When TACE+Systemic? When Systemic alone? Nice discussion @myESMO #ESMOAsia25 I agree with your conclusions @LorenzaRimassa
0
6
18
@myESMO
ESMO - Eur. Oncology
3 days
#ESMOAsia25: Studies in cancer of unknown primary (#CUP) highlight the need to perform routine comprehensive #GenomicProfiling and then provide access to the appropriate #TargetedTherapy. Find out more in the #ESMODailyReporter ➡️ https://t.co/5HEZ4mTxVu
0
6
19
@myESMO
ESMO - Eur. Oncology
3 days
#ESMOAsia25: #ClinicalTrials investigated antibody–drug conjugates (#ADCs) with payloads other than topoisomerase I inhibitors and targets beyond HER2 in attempts to minimise cross-resistance. Read more in the #ESMODailyReporter ➡️ https://t.co/CFSrjdjC5l @PTarantinoMD
0
10
23
@LorenzaRimassa
Lorenza Rimassa
4 days
Molecular profiling: When to test and how to test #TonyLim at #ESMOAsia25 @myESMO @LizzySmyth1
0
12
38
@LorenzaRimassa
Lorenza Rimassa
4 days
@myESMO #HCC CPG and PAGA: more similarities than differences #ESMOAsia25 @ArndtVogel @LizzySmyth1 #ChihKiangTan
0
1
12
@DrAngelaLamarca
Angela Lamarca
4 days
Session on radiotheranostics at @myESMO #ESMOAsia25 Chaired by #ElenaGarralda 💡PET Tumor Volume 💡SUV max 💡SUV mean 👉Dosimetry: pre-treatment and post-treatment 👉Selection of emitter and bystander effect 👀Long-term toxicity
2
3
9
@LorenzaRimassa
Lorenza Rimassa
4 days
0
3
12
@DrAngelaLamarca
Angela Lamarca
3 days
Thank you @myESMO #ESMOAsia25 for inviting me to review the current @myESMO Guidelines in #PancreaticCancer 📝Western vs PAGA version It’s crucial to adjust recommendations to each part of the world. Reality varies even within the same country. #ESMOGuidelines
2
5
26
@myESMO
ESMO - Eur. Oncology
4 days
#ESMOAsia25: Impressive results from the Chinese LUMINET-1 phase III trial confirm and extend previous findings with 177Lu-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumours (#GEP-NETs). Read more in the #ESMODailyReporter ➡️ https://t.co/5N7CAK9XA8
0
6
11
@myESMO
ESMO - Eur. Oncology
4 days
Josephine Contreras-Tolentino discusses why acknowledging population diversity matters. As shown at #ESMOAsia25, ethnicity differences can impact on presentation and tolerability, which can influence treatment selection. Read more: https://t.co/oaNS3dOlyd #ESMODailyReporter
1
4
8
@LorenzaRimassa
Lorenza Rimassa
4 days
@ModestDominik discusses precision medicine in #colorectal cancer treatment at #ESMOAsia25 @myESMO @LizzySmyth1
0
3
6